image: In his talk, Prof. Freeman will discuss the generation and actions of nitrogen oxide-derived fatty acid nitroalkenes in the context of their cell signaling actions, physiological responses and potential therapeutic effects as synthetic drug candidates.
Credit: Redox Medicine Society
Bruce A. Freeman, Irwin Fridovich Distinguished Professor and Chair at the University of Pittsburgh School of Medicine Department of Pharmacology & Chemical Biology, will introduce Redox Medicine 2024 with a key note talk titled "Small Molecule Electrophiles: Lessons from a Journey through Studying the Redox Chemistry of Nitrogen Oxides to Drug Development”.
The 26th International Conference of the Redox Medicine, Redox Medicine 2024, will take place on June 27-28 at Fondation Biermans Lapôtre in Paris, France.
Professor Freeman will discuss the generation and actions of nitrogen oxide-derived fatty acid nitroalkenes in the context of their cell signaling actions, physiological responses and potential therapeutic effects as synthetic drug candidates.
Contributions of Professor Bruce A. Freeman to Redox Biology
The research conducted by Professor Bruce. Freeman focuses on the study of oxidizing and free radical inflammatory mediators, including superoxide, hydrogen peroxide, nitric oxide (NO), and peroxynitrite, in the context of cellular signaling and disease mechanisms.
Professor Freeman's laboratory has identified important roles for reactive oxygen and nitrogen species in cellular signaling and disease processes. Initial research established the cellular sources of superoxide and hydrogen peroxide. Subsequent work revealed that NO interacts with superoxide to produce reactive nitrogen species, expanding the known functions of NO in cellular signaling beyond the activation of guanylate cyclase.
Additionally, Freeman's research into peroxynitrite, generated by the reaction of NO with superoxide, has highlighted its role in cellular dysfunction and disease. The laboratory's findings on the actions and targets of peroxynitrite have provided insights into the mechanisms of disease previously attributed to its precursor molecules.
Professor Freeman's research has contributed significantly to the understanding of redox biology, particularly in terms of the roles of reactive species in cellular signaling and disease. These contributions have implications for developing therapeutic strategies for diseases related to oxidative stress and inflammation.
Speakers Lineup of Redox Medicine 2024
Miria Ricchetti, Institut Pasteur, France – Keynote Speech on Day 2: “Redox Interactome in Physiopathology”
Bruce Freeman, University of Pittsburgh, USA – “A Nitroalkene-Based Therapy for Parkinson’s Disease – Preclinical Results”
Mario D. Cordero, Universidad Pablo de Olavide, Spain – “Mechanism of the SuperInflammasome Complexes in Human Diseases and Redox Signaling”
Christel Marquette, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), France – "Neuroinflammation, Alzheimer's Disease and Cell Death: Role of Redox"
Zaher El Beck, Karolinska Institutet, Sweden – “Epigenetic Modulators Link Mitochondrial Redox Homeostasis to Cardiac Function”
Tamara Tomin, TU Wien, Austria – “Metabolic regulation by Redox Signaling in the Heart”
Daniel Vaiman, DR1 INSERM, Institut Cochin, France – “New Insights into the Impact of Oxidative Stress in Hypertensive Diseases of Pregnancy”
Martin O. Bergö, Karolinska Institutet, Sweden – “Antioxidants Stimulating Blood Flow in Tumors”
Laurent Chatre, ISTCT, CNRS, Université de Caen Normandie, France – "The Reactive Species Interactome, Mitochondria, and the Gender-Brain Metabolism Nexus”
Miquel Mulero Abellán, Universitat Rovira i Virgili, Spain – “Redox in Gut Health and Nutrigenomics: Recent Advances and Perspectives”
Roberta Rizzo, Università degli Studi di Ferrara, Italy – “NADH: The Redox Sensor in Aging-Related Disorders”
Andrew Cumpstey, University of Southampton, United Kingdom – “Redox Implications of Supplementary Oxygen during Major Abdominal Surgery”
Carole Nicco, President of Redox Medicine Society – “Redox Medicine 2024: Biomarkers”
Sayuri Miyamoto, University of São Paulo, Brazil – “Identifying Oxidized Lipids in Neurodegenerative Diseases”
Jumana Saleh, Sultan Qaboos University, Oman – “Exploring Predictors of HDL Oxidative Stress Functionality in Post-Covid Disease and Relation to Severity”
Radia Tamarat, Institut de Radioprotection et de Sûreté Nucléaire (IRSN), France – "Redox, Radiotherapy and Biomarkers"
Govindasamy Mugesh, Indian Institute of Science, India – “Antioxidant and Prooxidant Nanozymes: From Cellular Redox Regulation to Next-Generation Therapeutics”
Jeffrey A. Johnson, University of Wisconsin, USA – “Targeting ‘Undruggable’ Proteins: New Approach for Treating Neurodegenerative Diseases”
George M. Spyrou, The Cyprus Institute of Neurology & Genetics, Cyprus – “Drug repurposing on Alzheimer's disease & NRF2 Modulation”
Stéphane Mouchabac, Hôpital Saint-Antoine, APHP, France – “Artificial Intelligence in NeuroInflammation, Biomarkers and Redox Medicine”
Maxime Barat, Université Paris Cité, Hôpital Cochin, France – "Artificial Intelligence & Algorithms: Applications in Redox Medicine & Radiology"
Duncan Emerton, Vice-President of Citeline, United Kingdom – “Pharma’s Search for Redox-Modulating Therapeutics”
Antonio Vila-Coro, IQVIA, Spain – “How to Develop a Drug – From Preclinical to Clinical”
More about Redox Medicine 2024
- Program
- Speakers
- Call for abstracts
- Supporters: Citeline and Mitologics
About Redox Medicine Society
Since 1998, the Redox Medicine Society (RMS), former ISANH, is dedicated to advancing the understanding and application of redox science in health and disease. RMS aims to facilitate the translation of basic knowledge of redox science into molecular medicine and to discover innovative new approaches to prevention, diagnosis and treatment. Through conferences, publications, and collaborations, the society seeks to promote innovation and excellence in the field of Redox Medicine and Science.